Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study

J Clin Psychopharmacol. 2013 Feb;33(1):118-20. doi: 10.1097/JCP.0b013e3182793843.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects*
  • Appetite Depressants / adverse effects
  • Appetite Depressants / therapeutic use*
  • Body Mass Index
  • Body Weight / drug effects
  • Brain / drug effects*
  • Brain / metabolism
  • Cannabinoid Receptor Antagonists / adverse effects
  • Cannabinoid Receptor Antagonists / therapeutic use*
  • Double-Blind Method
  • Drug Inverse Agonism
  • Eating / drug effects
  • Energy Intake / drug effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Overweight / chemically induced
  • Overweight / diagnosis
  • Overweight / drug therapy*
  • Overweight / psychology
  • Pilot Projects
  • Piperidines / adverse effects
  • Piperidines / therapeutic use*
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors*
  • Receptor, Cannabinoid, CB1 / metabolism
  • Rimonabant
  • Satiety Response / drug effects*
  • Schizophrenia / diagnosis
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology*
  • Signal Transduction / drug effects
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Appetite Depressants
  • CNR1 protein, human
  • Cannabinoid Receptor Antagonists
  • Piperidines
  • Pyrazoles
  • Receptor, Cannabinoid, CB1
  • Rimonabant